AI
20/20 Biolabs Inc.
AIDX · NASDAQ
$0.47 +0.21% (+$0.00)
1M -9.20%
Market Cap $5.76M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.69
46.7% upside
Current Price
$0.47
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AIDX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
61 /100
Fair P/S 2.82x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Rev. growth 43.03%
EPS growth N/A
FCF growth N/A
Profitability
11 /100
Weak Gross margin 29.56%
Net margin 182.82%
Op. margin 162.87%
Quality
2 /100
Poor ROIC 0.26%
ROA 0.09%
Asset turnover 0.00x
Debt
5 /100
High Current ratio 0.60x
Int. coverage 0.02x
Debt/Equity N/A
Stability
8 /100
Unstable Beta 1.54x
Rev. volatility 61.85%
EPS volatility 412.29%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AIDX
Online
Sector
Healthcare
Industry
Medical - Care Facilities
CEO
Jonathan Cohen
Employees
14
Headquarters
Gaithersburg